Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis

Total Knee Arthroplasty Clinical Trial

— FHK-CK  

Official title:

Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis Indicated for the Treatment of Primary and Secondary First Line Gonarthrosis and Revision Arthroplasty - 2 Years Follow-up - A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06124482
• Other study ID #: 2022-01
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2024
• Est. completion date: February 2028

Study information

• Verified date: February 2024
• Source: FH ORTHO
• Contact: Aroua JABRI
• Phone: 07 72 23 34 74
• Email: a.jabri[@]fhortho.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked).

The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact.

By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 92
• Est. completion date: February 2028
• Est. primary completion date: February 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient requiring knee arthroplasty for primary or secondary gonarthrosis:

• For primary intention arthroplasty: Patient with either

• major axial deviation,

• major peripheral failure or

• bone defect;

• For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects.

• Patient able to understand and answer the questionnaires provided by the protocol;

• Subject affiliated to a health insurance system or is a beneficiary;

• Signed informed consent form (ICF) for participation to the research.

Exclusion Criteria:

• Patient with an ongoing acute infection, outside knee to be operated;

• Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications;

• Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium);

• Patient with a dependency (drug, alcohol,…) that could affect his/ her ability to comply with the protocol, at the investigator's discretion;

• Patient requiring knee reconstruction;

• Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator;

• Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis;

• Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed.

• Vulnerable subjects :

• Pregnant, parturient, or breastfeeding women,

• Subject deprived of liberty, hospitalized without consent or admitted to a health or social establishment for purposes other than that of research,

• Minor,

• Adult under protective supervision (tutorship, curatorship),

• Subject not able to understand the subject information leaflet (e.g. for linguistic or psychiatric reasons) and/or to give informed consent

Related Conditions & MeSH terms

• Total Knee Arthroplasty

Intervention

Device:
• Total Knee arthroplasty
The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.

Locations

Country	Name	City	State
France	Hôpital Privé La Châtaigneraie	Beaumont
France	Hôpital Beaujon AP-HP	Clichy
France	Hôpital Raymond Poincaré AP-HP	Garches
France	Centre Hospitalier Régional Universitaire de Nancy	Nancy
France	Groupe Hospitalier Pitié Salpêtrière AP-HP	Paris

Sponsors (2)

Lead Sponsor	Collaborator
FH ORTHO	Slb Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Functional performance	Evolution of the functional performance of FHK®-CK prosthesis using the KSS scoring system, which is composed of 2 sections : Knee score (KSKS) and function score (KSFS). Each section is scored on a scale of 0 to 100 ; the higher the score, the better the overall functionality of the knee. The functional performance of the FHK®-CK prosthesis will be demonstrated at 2 years if an improvement of the KSKS and KSFS scores at least equal to the Minimal Clinically Important Difference (MCID) values is observed.	Baseline (preoperatively), at 6 weeks, 6 months, 12 months and 24 months after surgery.
Secondary	Adverse and serious adverse events evaluation	Occurrence of adverse and serious adverse events, including complication	Through study completion, an average of 2 years
Secondary	Revision rate evaluation	Revision rate	At 6 weeks, 6 months, 12 months and 24 months after surgery.
Secondary	Evaluation of patient's tolerance of the FHK-CK prosthesis	Tolerance assessed by the surgeon with a 4-Likert scale (very bad - bad - good - very good)	At 6 weeks, 6 months, 12 months and 24 months after surgery.
Secondary	Device deficiencies evaluation	Number of device deficiencies and description of deficiencies.	Through study completion, an average of 2 years
Secondary	Quality of life assessment	Self assessement of quality of life using the medical outcome study Short Form (SF-12) scale (General Quality of life score) from 0 "worst quality of life" to 100 "best quality of life".	Baseline (preoperatively), at 6 months, 12 months and 24 months after surgery.
Secondary	Quality of life assessment	Self assessement of quality of life using the Oxford Knee score (OKS), especially developed for knee surgery. The OKS is derived from 12 questions assessed on a Likert scale with values from 0 to 4; a summative score is then calculated where 48 is the best possible score (least symptomatic) and 0 is the worst possible score (most symptomatic)	Baseline (preoperatively), at 6 months, 12 months and 24 months after surgery.
Secondary	Patient's satisfaction about FHK®-CK prosthesis	Satisfaction assessed by the patient with a 4-Likert scale ((very bad - bad - good - very good)	At 6 months, 12 months and 24 months after surgery
Secondary	Surgeon's satisfaction about FHK®-CK equipment	Satisfaction assessed by the surgeon for each surgery performed with FHK®-CK with a specific questionnaire developed including 9 questions with either a lickert scale or a yes/no response.	During surgery